Natera rises after launching new genetic test for rare diseases

Natera

12/03/2026 12:14

** Shares of genetic testing firm Natera NTRA.O rise 1.4% to $197.59 premarket

** Co launches Zenith Genomics, a whole genome sequencing test aimed at speeding diagnosis of rare and ultra-rare diseases - NTRA

** Rare diseases affect about 30 million Americans and can take years to diagnose, co says

** Test is designed to spot hard-to-detect genetic disorders and help guide treatment and long-term care

** Zenith Genomics developed with genome analysis firm MyOme and will be offered across the U.S. using Natera's existing network - NTRA

** Co says growing use of genetic testing and insurance coverage should support adoption

** Shares up ~44% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))